Anticoagulation With Otamixaban and Ischemic Events in Non–ST-Segment Elevation Acute Coronary Syndromes
Why the study?
Does otamixaban reduce the composite of all-cause death or new myocardial infarction compared to unfractionated heparin plus eptifibatide in patients with NSTE-ACS undergoing a planned early invasive strategy?
Population
13,229 patients with non-ST-segment elevation acute coronary syndromes undergoing a planned early invasive…
Comparison
Otamixaban vs Unfractionated heparin plus eptifibatide at the…
Design
RCT, Randomized, double-blind
Follow-up
through day 7
Authors
Discussion
Loading...
Member takes
Implication
Otamixaban does not reduce ischemic events in NSTE-ACS; challenges its further development and reinforces heparin-based regimens.
Structured PICO
Does otamixaban reduce the composite of all-cause death or new myocardial infarction compared to unfractionated heparin plus eptifibatide in patients with NSTE-ACS undergoing a planned early invasive strategy?
P
Population
13,229 patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) undergoing a planned early invasive strategy, multinational (55 countries).
I
Intervention
Otamixaban (intravenous bolus of 0.080 mg/kg followed by an infusion of 0.140 mg/kg per hour)
C
Comparator
Unfractionated heparin plus eptifibatide at the time of percutaneous coronary intervention
O
Outcome
Composite of all-cause death or new myocardial infarction through day 7composite
In patients with NSTE-ACS undergoing an early invasive strategy, the novel factor Xa inhibitor otamixaban did not reduce ischemic events but significantly increased bleeding compared to unfractionated heparin plus eptifibatide.
Cite This Study
Philippe Gabríel Steg (2013) studied this question.